SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001819790-22-000042
Filing Date
2022-11-09
Accepted
2022-11-09 08:48:52
Documents
71
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tars-20220930.htm   iXBRL 10-Q 1463622
2 EX-31.1 exhibit311-93022.htm EX-31.1 12779
3 EX-31.2 exhibit312-93022.htm EX-31.2 13035
4 EX-32.1 exhibit321-93022.htm EX-32.1 9974
5 EX-32.2 exhibit322-93022.htm EX-32.2 9916
  Complete submission text file 0001819790-22-000042.txt   6748880

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tars-20220930.xsd EX-101.SCH 42239
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT tars-20220930_cal.xml EX-101.CAL 88923
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT tars-20220930_def.xml EX-101.DEF 161475
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tars-20220930_lab.xml EX-101.LAB 514069
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tars-20220930_pre.xml EX-101.PRE 337473
65 EXTRACTED XBRL INSTANCE DOCUMENT tars-20220930_htm.xml XML 1231628
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39614 | Film No.: 221370835
SIC: 2836 Biological Products, (No Diagnostic Substances)